TL;DR

Polycystic kidney disease (PKD) is a group of genetic disorders in which numerous fluid-filled cysts develop in the kidneys and grow over time, compressing normal renal tissue. The most common form is autosomal dominant polycystic kidney disease (ADPKD), caused by mutations in the PKD1 or PKD2 genes. As cysts expand, they raise blood pressure, reduce kidney function, and can eventually lead to end-stage renal disease. ADPKD affects roughly 1 in 400 to 1 in 1,000 people and is the most common inherited kidney disorder. Conventional care focuses on blood-pressure control, slowing cyst growth, and managing complications; tolvaptan is currently the only approved disease-modifying drug in many countries. Traditional Chinese Medicine classifies PKD under patterns such as lumbar pain, accumulation, and edema, emphasizing kidney deficiency, blood stasis, and damp turbidity, treated by tonifying the kidney, activating blood circulation, and draining dampness. Ayurveda interprets the condition as a Kapha and Vata imbalance with Ama obstructing the Mutravaha srotas, using herbs such as Punarnava, Gokshura, and Varuna alongside detoxification therapies. Folk traditions emphasize low-sodium diets, ample hydration, and avoidance of nephrotoxins. Energy-healing approaches view PKD as deep-seated energetic and emotional stagnation, using qigong, tai chi, Reiki, and sound healing as adjunctive mind-body support. All four systems share the same goals—slow functional decline, control blood pressure, relieve pain, and improve quality of life—but they speak different diagnostic languages and use different tools; an integrative approach is often more complete than any single system alone.

Definition

Polycystic kidney disease (PKD) is a family of inherited disorders characterized by the development of numerous cysts in both kidneys. The cysts arise from renal tubular epithelial cells, gradually enlarge, fill with clear or blood-tinged fluid, and compress normal renal parenchyma, leading to loss of functioning nephrons and declining kidney function. Based on inheritance pattern, PKD is divided into two major forms:

• Autosomal dominant polycystic kidney disease (ADPKD): Accounts for about 90% of cases, caused by mutations in PKD1 or PKD2. Symptoms usually appear in adulthood, although childhood onset can occur.
• Autosomal recessive polycystic kidney disease (ARPKD): Much rarer, caused by PKHD1 mutations, and typically presents with severe kidney and liver involvement in fetuses or newborns.

In addition to renal cysts, ADPKD is frequently associated with extrarenal manifestations: hepatic cysts, intracranial aneurysms, cardiac valvular abnormalities, abdominal wall hernias, and colonic diverticula. The disease progresses continuously; most patients develop chronic kidney disease in the fourth to sixth decades of life, and approximately half reach end-stage renal disease (ESRD) before age 60, requiring dialysis or kidney transplantation. PKD is therefore not simply a “kidney cyst” condition but a multisystem, lifelong chronic disease.

Epidemiology

ADPKD is the most common inherited kidney disease worldwide, with an incidence of about 1 per 400 to 1,000 live births and a prevalence estimated between 1 in 2,000 and 1 in 4,000. Because penetrance is nearly 100%, virtually everyone who carries a pathogenic mutation will eventually develop kidney cysts, although expressivity varies enormously: some individuals maintain stable renal function throughout life, while others require renal replacement therapy in middle age. Overall prevalence is similar in men and women, but men tend to progress more rapidly and develop more severe hypertension.

ADPKD accounts for approximately 5% to 10% of all cases of ESRD globally and is the fourth leading cause of kidney failure from inherited or systemic disease. In the United States, direct medical costs exceed $7 billion annually, driven largely by dialysis and transplantation. Epidemiologic data from China are more limited, but clinical recognition is rising as ultrasound and genetic testing become more widely available.

Conventional-Medicine Perspective

Pathophysiology

The molecular basis of ADPKD is loss-of-function mutation in PKD1 or PKD2, which encode polycystin-1 (PC1) and polycystin-2 (PC2), respectively. These proteins form a complex at primary cilia and cell-cell junctions and regulate intracellular calcium signaling, cell proliferation, differentiation, and fluid secretion. When either gene is mutated, renal tubular epithelial cells proliferate excessively, secrete fluid, and lose normal polarity, producing cysts that expand progressively.

Cyst growth often follows exponential kinetics, with individual cyst doubling times ranging from months to years. As cyst number and volume increase, normal kidney tissue is compressed, ischemic, and fibrotic; the renin-angiotensin system is activated, causing hypertension and accelerating glomerulosclerosis. PKD1 mutations are generally associated with larger cysts, earlier onset, and faster progression than PKD2 mutations, which tend to delay ESRD by roughly 15 to 20 years.

Assessment and Screening

Imaging is the cornerstone of ADPKD diagnosis. Ultrasound is the preferred screening tool because it is noninvasive, inexpensive, and repeatable. Typical findings include bilaterally enlarged kidneys with multiple corticomedullary cysts. In at-risk individuals aged 15 to 39, the presence of three or more cysts is highly sensitive for diagnosis. CT and MRI are more precise for cyst counting, volume measurement, and complication assessment; MRI is especially useful in clinical trials and for monitoring response to tolvaptan.

Genetic sequencing can confirm PKD1/PKD2 mutations and is particularly valuable when imaging is inconclusive, family history is absent, onset is early, or prenatal or preimplantation genetic diagnosis is desired. All diagnosed patients should undergo regular monitoring of blood pressure, kidney function (eGFR, serum creatinine), urine protein, electrolytes, lipids, and glucose, as well as evaluation for extrarenal complications. Adults over 30 should have at least one head MRA to screen for intracranial aneurysms, particularly if a first-degree relative has had an aneurysm or subarachnoid hemorrhage.

Blood Pressure and Cardiovascular Risk Management

Hypertension is one of the earliest and most common complications of ADPKD, affecting about 60% of patients while renal function is still normal. Elevated blood pressure accelerates renal functional decline and promotes left ventricular hypertrophy, making it a major contributor to cardiovascular events and mortality in ADPKD. Target blood pressure is generally below 130/80 mmHg, and younger patients may aim for approximately 120/75 mmHg. First-line agents are angiotensin-converting-enzyme inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs), which have the strongest evidence for lowering intraglomerular pressure and reducing proteinuria.

Cardiovascular risk in ADPKD is higher than in the general chronic kidney disease population, partly because of early atherosclerosis, left ventricular remodeling, and increased arterial stiffness. Comprehensive management should therefore also include smoking cessation, weight control, lipid management, diabetes control, regular physical activity, and sodium restriction.

Disease-Modifying Pharmacotherapy

Tolvaptan is a selective vasopressin V2-receptor antagonist. It reduces cyst fluid secretion by inhibiting aquaporin-2 in collecting-duct principal cells, thereby slowing total kidney-volume growth and eGFR decline. The TEMPO 3:4 trial demonstrated that tolvaptan significantly slowed kidney-volume growth and eGFR decline in ADPKD patients. The subsequent REPRISE trial confirmed benefit even in later-stage chronic kidney disease.

Tolvaptan is approved by the FDA, EMA, and China NMPA for adults with ADPKD at risk of rapid progression. Patient selection, monitoring of liver enzymes (because hepatotoxicity is a rare but serious risk), and serum sodium are essential. Polyuria and thirst are common, so adherence and fluid management are critical to treatment success.

Complication Management and End-Stage Care

Common ADPKD complications include cyst infection, hemorrhage, stone formation, pain, hematuria, and urinary tract infection. Cyst infection can be difficult to diagnose and often requires CT, MRI, or radionuclide imaging. Treatment calls for lipophilic antibiotics that penetrate cyst walls, such as ciprofloxacin, metronidazole, or trimethoprim-sulfamethoxazole. Pain is best managed initially with nonpharmacologic measures (positioning, heat, percutaneous drainage) rather than long-term nonsteroidal anti-inflammatory drugs, which can worsen kidney function.

Kidney stones—often uric acid or calcium oxalate—are prevented primarily by high fluid intake and urine alkalinization when appropriate. Patients who reach ESRD may choose hemodialysis, peritoneal dialysis, or kidney transplantation. ADPKD patients generally have better post-transplant survival than many other ESRD groups because the disease does not recur in the transplanted kidney. Massively enlarged kidneys causing severe pain, recurrent infection, or limiting transplant space may be treated with unilateral or bilateral native nephrectomy.

Traditional-Medicine Perspective

Traditional Chinese Medicine: Kidney Deficiency, Blood Stasis, and Damp Turbidity

Although classical TCM texts do not contain a disease name identical to “polycystic kidney,” the clinical manifestations can be categorized as lumbar pain (yao tong), accumulation (ji ju), edema (shui zhong), lin syndrome (lin zheng), or bloody urine (xue niao). TCM holds that the kidney is the foundation of congenital essence, governs water metabolism, and rules the bones and marrow. The development of PKD is often attributed to congenital kidney-essence deficiency; the progressive formation of cysts is understood as a pathological product of phlegm-stasis interaction and water-damp retention.

Common pattern differentiations include:

• Kidney-qi deficiency: low back soreness, fatigue, nocturia, pale tongue, deep thin pulse.
• Kidney-yin deficiency: tidal fever, night sweats, dry mouth, sore low back, red tongue with little coating, thin rapid pulse.
• Damp-heat pouring downward: painful, scanty, or turbid urine, hematuria, abdominal and lumbar distention, red tongue with yellow greasy coating, slippery pulse.
• Blood stasis internally obstructing: fixed stabbing lumbar pain, large cysts, dusky complexion, purple tongue or ecchymosis.
• Spleen-kidney yang deficiency: cold intolerance, edema of the lower limbs, poor appetite, loose stools, pale swollen tongue with tooth marks.

The general treatment principle is to tonify the kidney, activate blood circulation, drain dampness, and resolve turbidity. For kidney-qi deficiency, formulas such as Jinkui Shenqi Wan or Yougui Wan may be modified; for kidney-yin deficiency, Liuwei Dihuang Wan or Zuogui Wan; for damp-heat, Bazheng San or Bixie Fenqing Yin; for blood stasis, Xuefu Zhuyu Tang or Guizhi Fuling Wan. Commonly used herbs include Astragalus (huangqi), Codonopsis (dangshen), Rehmannia (dihuang), Dioscorea (shanyao), Cornus (shanyurou), Poria (fuling), Alisma (zexie), Salvia (danshen), Ligusticum (chuanxiong), Leonurus (yimucao), Hedyotis diffusa (baihuasheshecao), Scutellaria barbata (banzhilian), and Smilax glabra (tufuling).

Acupuncture commonly uses points such as Shenshu, Pangguangshu, Sanyinjiao, Zusanli, Yinlingquan, Taixi, Shuifen, and Guanyuan, often combined with moxibustion to warm yang and promote fluid metabolism. Modern research suggests that kidney-tonifying and blood-activating herbs may exert renoprotective effects by modulating cell proliferation, reducing inflammation and oxidative stress, and ameliorating renal interstitial fibrosis. It must be emphasized that TCM cannot alter the underlying genetic mutation or replace evidence-based targeted therapy such as tolvaptan; it is used mainly for symptom control and as an adjunct to slow progression.

Ayurveda: Kapha-Vata Imbalance and Obstruction of Mutravaha Srotas

Ayurveda understands the human being as an integrated system of three doshas—Vata, Pitta, and Kapha—and seven tissue layers (dhatus). The urinary system is governed by Mutravaha srotas, the channels responsible for urine formation and elimination, and depends on harmonious Kapha and Vata function. From an Ayurvedic perspective, PKD can be understood as excessive Kapha accumulation forming cystic structures, combined with Vata imbalance causing abnormal proliferation and drying, Pitta contributing to inflammation and metabolic disturbance, and Ama (undigested toxic residue) obstructing the subtle channels (srotas).

Ayurvedic diagnosis uses Nadi pariksha (pulse examination), Jihva pariksha (tongue diagnosis), Drika pariksha (eye examination), detailed history taking, and Mutra pariksha (urine examination) to assess the individual’s Prakriti (constitution) and Vikriti (current imbalance). Treatment aims to eliminate Ama, restore dosha balance, clear Mutravaha srotas, and protect Mamsa (muscle) and Meda (fat) dhatus, ultimately supporting kidney function.

Commonly used herbs and formulations include:

• Punarnava (Boerhavia diffusa): A classic diuretic and kidney restorative that helps reduce edema and support renal function.
• Gokshura (Tribulus terrestris): Supports urinary and reproductive health and has diuretic and anti-inflammatory properties.
• Varuna (Crataeva nurvala): Traditionally used for urinary stones and cystic conditions to improve urine flow.
• Chandraprabha vati: A classical compound formulation used for genitourinary and metabolic disorders.
• Guggulu (Commiphora mukul): Promotes blood circulation, resolves phlegm, and reduces inflammation.
• Ashwagandha (Withania somnifera) and Shatavari (Asparagus racemosus): Tonify the kidneys and enhance overall resilience.

External therapies include Abhyanga (oil massage) with warming oils such as Mahanarayana taila or Dhanvantaram taila to balance Vata, and Basti (medicated enema), especially Majja Basti or Mustadi Yapana Basti, to nourish marrow and clear lower-body channels. Dietary advice emphasizes warm, light, easily digestible food; avoidance of excessive salt, cold, oily, or heavy foods; and moderate intake of gourd-family vegetables, mung beans, barley, ginger, and coriander. Preliminary modern research indicates that Punarnava and related herbs possess antioxidant, anti-inflammatory, and nephroprotective effects, but high-quality clinical trials specific to PKD remain limited.

Folk Wisdom

Folk traditions around the world have limited specific knowledge of PKD but have accumulated practical wisdom about kidney protection, fluid metabolism, and detoxification. These approaches cannot replace medical treatment but can serve as useful lifestyle adjuncts.

• Adequate hydration: Drinking 2.5 to 3 liters of water daily (individualized for cardiac and renal status) helps dilute urine and reduces the risk of stones and infection. Urine should be pale yellow.
• Low-sodium diet: Limiting sodium assists blood-pressure control. Most guidelines suggest less than 5 grams of salt per day, avoiding pickled, processed, and fast foods.
• Avoid nephrotoxins: Use nonsteroidal anti-inflammatory drugs, certain antibiotics, aristolochic-acid-containing herbs, contaminated supplements, and radiographic contrast with caution; stop smoking and limit alcohol.
• High-quality, low-protein diet: When kidney function declines, protein intake may be moderated to 0.6–0.8 g/kg/day, emphasizing high-quality sources such as fish, eggs, lean meat, and legumes to reduce nitrogenous waste.
• Potassium and phosphorus awareness: As renal function worsens, adjust intake of bananas, oranges, nuts, dairy, and organ meats based on serum potassium and phosphorus levels.
• Warm compresses: Some patients find relief from lumbar aching with warm towels or moxibustion boxes applied to the lower back.
• Regular routines and emotional balance: Avoiding overwork, sleep deprivation, and chronic emotional suppression is traditionally viewed as protective for the kidneys; TCM holds that fear injures the kidney.

It is especially important to consult a nephrologist before using any herb, supplement, or “detox” regimen, because inappropriate products may increase renal burden or interfere with conventional medications.

Energy Healing

Energy-healing frameworks do not view PKD solely as a structural renal disease. Instead, they connect it to deeply held emotions, unexpressed feelings, inherited family trauma, and stagnation in the water-element energy system. In many energy-medicine traditions, the kidneys are seen as the storehouse of life essence, fear, and willpower; the encapsulated form of cysts is sometimes interpreted as the body’s attempt to isolate and contain emotions or toxins that feel too difficult to process.

Common energy and mind-body practices include:

• Qigong and daoyin: Slow breathing combined with abdominal and lumbar movement promotes qi and blood circulation, strengthens core muscles, and regulates autonomic function. Baduanjin, Wuqinxi, and the “chui” sound in Liu Zi Jue are traditionally associated with the kidneys.
• Tai chi: Improves balance, lowers blood pressure, and reduces chronic pain and anxiety, making it particularly suitable for ADPKD patients with hypertension.
• Reiki: Hands-on or distant energy transmission promotes relaxation, pain relief, and better sleep.
• Sound healing and singing bowls: Low-frequency vibration is thought to promote deep tissue relaxation and fluid metabolism, although evidence is largely experiential.
• Meditation and mindfulness: Help manage the uncertainty and anxiety of chronic illness and improve blood-pressure variability and sleep quality.
• Earthing and nature therapy: Walking barefoot on natural ground or spending time in forests may lower inflammatory markers and stress hormones.

The value of energy healing lies in supporting whole-person wellbeing rather than directly eliminating cysts. It is best used as an adjunct to conventional and traditional medical care, helping patients build inner stability, improve quality of life, and maintain treatment adherence.

Four-System Comparison

| Dimension | Conventional Medicine | Traditional Chinese Medicine | Ayurveda | Folk Wisdom / Energy Healing |

|---|---|---|---|---|

| Core cause | PKD1/PKD2 mutations cause polycystin dysfunction and progressive cyst growth | Congenital kidney-essence deficiency, phlegm-stasis interaction, water-damp retention | Kapha accumulation, Vata imbalance, Ama obstructing Mutravaha srotas | Lifestyle imbalance, emotional suppression, disturbed fluid metabolism |

| Key diagnosis | Ultrasound/CT/MRI, genetic testing, eGFR, blood-pressure monitoring | Four diagnostic methods, pattern differentiation (kidney deficiency, damp-heat, blood stasis, etc.) | Nadi pariksha, tongue diagnosis, urine examination, constitution assessment | Symptom observation, habit review, somatic and emotional awareness |

| Treatment goal | Slow cyst growth, control blood pressure, preserve kidney function, manage complications | Tonify kidney, activate blood, drain dampness, resolve turbidity, relieve symptoms | Balance doshas, clear Ama, unblock urinary channels | Protect the kidneys, promote diuresis, reduce stress, improve lifestyle |

| Core interventions | ACEI/ARB, tolvaptan, low-sodium diet, complication management, dialysis/transplant | Internal herbal formulas, acupuncture, moxibustion, daoyin | Punarnava, Gokshura, Varuna, Basti, Abhyanga, dietary correction | Adequate hydration, low-sodium diet, avoid nephrotoxins, qigong/tai chi/meditation |

| Strengths | Strong evidence base, quantifiable monitoring, disease-modifying therapy available | Individualized pattern differentiation, symptom and quality-of-life improvement | Holistic constitution-based care, emphasis on detoxification and energy balance | Easy to practice daily, low cost, addresses mind and body together |

| Limitations | Cannot cure genetic cause, medications have side effects and costs | Limited high-quality randomized trials; cannot replace targeted therapy | Scientific evidence limited; requires trained Ayurvedic practitioner | Cannot replace medical treatment; beware of pseudoscience and delayed care |

For patients who want to integrate all four systems, the practical challenge is rarely a shortage of information—it is finding practitioners who understand more than one paradigm. Rebirthealth addresses this by connecting patients with practitioners across conventional medicine, TCM, Ayurveda, and mind-body healing, allowing you to receive coordinated, multi-system input on a single case. If you would like a more complete cross-system plan for managing your polycystic kidney disease, you can post a case on Rebirthealth.

FAQ

1. Is polycystic kidney disease hereditary? Yes. The most common form, ADPKD, is caused by mutations in PKD1 or PKD2 and is inherited in an autosomal dominant pattern. If one parent has ADPKD, each child has a 50% chance of inheriting the mutation. About 5% to 10% of cases have no family history and arise from new mutations.

2. Will PKD always progress to kidney failure? Not necessarily. Although penetrance is high, expressivity varies widely. Some patients maintain stable kidney function for life, while others need dialysis or transplantation before age 60. PKD1 mutations, male sex, early-onset hypertension, heavy proteinuria, and recurrent cyst infections suggest faster progression.

3. Can PKD be cured? Currently there is no cure. Treatment aims to slow cyst growth, control blood pressure, manage complications, and provide timely renal replacement therapy. Kidney transplantation replaces failed kidney function but does not change the genetic background.

4. Is tolvaptan suitable for everyone with PKD? No. Tolvaptan is generally reserved for adults with ADPKD at risk of rapid progression and must be prescribed by a specialist. Liver enzymes and serum sodium need monitoring, and side effects such as polyuria and thirst can be significant.

5. Can people with PKD have children? Yes, but genetic counseling is recommended. Prenatal diagnosis (amniocentesis or chorionic villus sampling) or preimplantation genetic testing (PGT) can reduce the chance of passing on the disease.

6. What should daily diet look like for PKD patients? A low-sodium diet, ample fluid intake, high-quality low-protein intake when kidney function declines, and potassium/phosphorus restriction based on lab results are generally advised. Avoid nephrotoxins. A renal dietitian and nephrologist should individualize the plan.

7. Does PKD increase cancer risk? The cysts themselves are not cancerous, but ADPKD patients have a slightly increased risk of renal cell carcinoma, and the cysts can mask early tumors. Persistent hematuria or thickening or irregularity of a cyst wall warrants further investigation.

8. Is back pain always a sign of cyst growth? Not always. Back pain in PKD may result from cyst stretching, hemorrhage, infection, or stones, but it can also be musculoskeletal. Persistent or worsening pain should be evaluated by a clinician.

9. Can Chinese herbs eliminate kidney cysts? There is no high-quality evidence that Chinese herbs or any herbal remedy can eliminate existing renal cysts. TCM is used mainly to improve symptoms, regulate constitution, and support slowing of progression; it does not replace conventional targeted therapy.

10. Can people with PKD exercise? Yes, but high-impact contact sports and direct abdominal trauma should be avoided. Low-impact activities such as walking, swimming, tai chi, and qigong are generally beneficial.

11. Should family members be screened? Yes. First-degree relatives of an ADPKD patient should undergo ultrasound screening and, when appropriate, genetic testing. Early detection allows earlier blood-pressure control and progression monitoring.

12. Is energy healing useful for PKD? Energy healing cannot shrink cysts or repair genes, but it may serve as a supportive adjunct for stress reduction, sleep improvement, blood-pressure modulation, and quality of life. It should be used within, not instead of, a conventional medical framework.

Next Steps

If you or a family member has recently been diagnosed with PKD, consider the following action plan:

1. Establish specialist follow-up: See a nephrologist or genetic kidney disease clinic for ultrasound/CT/MRI, genetic testing, blood pressure, eGFR, urine protein, electrolytes, and comprehensive renal assessment.

2. Control blood pressure rigorously: Blood pressure is one of the most powerful modifiable risk factors. Aim for below 130/80 mmHg in most patients, and prefer ACE inhibitors or ARBs.

3. Assess rapid-progression risk: Use age, kidney function, total kidney volume, and mutation type to determine whether you are a candidate for tolvaptan therapy.

4. Screen for extrarenal complications: Include head MRA for intracranial aneurysms, echocardiography for valvular disease, and abdominal imaging for hepatic cysts.

5. Optimize lifestyle: Maintain adequate hydration, reduce sodium intake, stop smoking, limit alcohol, exercise regularly, maintain a healthy weight, and avoid nephrotoxic drugs.

6. Consider cross-system support: In addition to conventional care, consult a TCM or Ayurvedic practitioner experienced in kidney conditions for individualized constitutional support and symptom management; use qigong, tai chi, or mindfulness for stress and emotional regulation.

7. Seek integrated multi-system analysis: If you would like coordinated input from conventional medicine, TCM, Ayurveda, and mind-body healing in one place, you can post a case on Rebirthealth and receive a collaborative, cross-system management plan tailored to your situation.

Polycystic kidney disease is a long journey. Early intervention, regular monitoring, and integrated multi-system support are the keys to slowing progression and preserving quality of life.

References

1. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287-1301. PMID: 17434405

2. Chebib FT, Torres VE. Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016. Am J Kidney Dis. 2016;67(5):792-810. PMID: 26916154

3. Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet. 2019;393(10174):919-935. PMID: 30859953

4. Chapman AB, Devuyst O, Eckardt KU, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015;88(1):17-27. PMID: 25786098

5. Ong AC, Devuyst O, Knebelmann B, Walz G. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet. 2015;385(9981):1993-2002. PMID: 26090645

6. Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med. 2008;359(14):1477-1485. PMID: 18832246

7. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407-2418. PMID: 23121363

8. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377(20):1930-1942. PMID: 29141187

9. Ecder T. Cardiovascular disease in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2011;26(3):806-813. PMID: 21209135

10. Igarashi P, Somlo S. Polycystic kidney disease. J Am Soc Nephrol. 2002;13(3):738-742. PMID: 11856778

11. Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363(9):820-829. PMID: 20813852

12. Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med. 1993;329(5):332-342. PMID: 8321261